Radiation oncologist · Universitätsklinikum Heidelberg · Germany (DE) · Oncology
Data minimisation
Cadence target for Tier 3: 1 per year (assumption)
3 of 1 expected engagements
All engagements including drafts, newest first
| Date | Type | Format | MSL | Product | Topics | Insights | Flags | Status | |
|---|---|---|---|---|---|---|---|---|---|
| 19 May 2026 | Medical education | Virtual | Rachel Adeyemi | Vantrexa | Chemotherapy-free first lineSequencing after progression+1 | 0 | — | Reviewed | ENG-0113 |
| 14 May 2026 | Advisory board | Phone | Rachel Adeyemi | Vantrexa | Comparator checkpoint monotherapyDuration of response+1 | 0 | — | Reviewed | ENG-0067 |
| 10 May 2026 | Scientific exchange | Virtual | Rachel Adeyemi | Vantrexa | Brain-metastasis subgroup dataChemotherapy-free first line | 1 | — | Reviewed | ENG-0077 |
| 29 Jan 2026 | Scientific exchange | Phone | Rachel Adeyemi | Vantrexa | Chemotherapy-free first line | 0 | — | Reviewed | ENG-0111 |
19 May 2026
Chemotherapy-free first line, Sequencing after progression, Infusion-reaction management
14 May 2026
Comparator checkpoint monotherapy, Duration of response, Brain-metastasis subgroup data
10 May 2026
Brain-metastasis subgroup data, Chemotherapy-free first line
29 Jan 2026
Chemotherapy-free first line
Universitätsklinikum Heidelberg
Pathologist
Thoracic medical oncologist
Academic nephrologist
Community nephrologist
Academic nephrologist
Primary care physician
Allergist
Allergist